# NSAID Selection and Safety Monitoring in Feline Chronic Pain Management ## Key Takeaways - Feline NSAID selection for chronic pain hinges on understanding COX-1/COX-2 selectivity, feline hepatic metabolism (limited glucuronidation prolonging half-lives), and individual patient risk factors. - Baseline assessment is critical, including serum biochemistry (renal parameters), urinalysis (specific gravity, protein-to-creatinine ratio), blood pressure, and body condition score, to identify contraindications like IRIS stage 2+ CKD or uncontrolled hypertension. - Monitoring protocols require rechecks at 2-4 weeks post-initiation and every 3-6 months thereafter, with owners instructed to report gastrointestinal signs, lethargy, or increased thirst as early indicators of adverse events. - Adverse event triggers such as azotemia, proteinuria, hypertension, or gastrointestinal signs mandate NSAID dose reduction or discontinuation, with supportive care and investigation of underlying causes. - Only use NSAID products with feline label approval or published safety data, adhering to species-specific dosing and regulatory guidance to mitigate risks associated with cats' unique drug handling and narrower therapeutic index. - COX-2 preferential NSAIDs are generally favored for chronic pain, but selectivity does not eliminate renal or gastrointestinal risk, necessitating vigilant monitoring due to COX-2's constitutive roles in these tissues. --- Feline chronic pain, most commonly arising from degenerative joint disease, presents a persistent clinical challenge. The veterinary literature has moved from a historical reluctance to use nonsteroidal anti-inflammatory drugs (NSAIDs) in cats toward an evidence-informed position that these agents, when selected and monitored properly, can provide meaningful analgesia. This article addresses the practicing veterinarian who must choose among available NSAIDs, establish baseline risk, and implement a monitoring protocol that balances analgesic benefit against renal, hepatic, and gastrointestinal safety. The scope is limited to chronic pain management in cats, acute pain protocols and off-label recommendations lacking published safety data are excluded. The central clinical question is not whether NSAIDs work in cats, but which cat, at which life stage, with which comorbidities, can safely receive long-term therapy. Answering that question requires an understanding of cyclooxygenase (COX) biology, the pharmacokinetic peculiarities of feline drug handling, and the evidence base for monitoring intervals and laboratory thresholds. This article provides a decision framework grounded in those principles, with explicit attention to areas where the evidence remains contested or incomplete. ## At a Glance | Parameter | Clinical Consideration | |---|---| | COX-1 versus COX-2 selectivity | Selective COX-2 inhibition preserves gastric prostaglandins while targeting inflammatory mediators, a distinction established in early pharmacological models | | Feline hepatic metabolism | Cats have limited glucuronidation capacity, prolonging half-lives of certain NSAIDs and increasing accumulation risk with repeated dosing | | Baseline assessment | Serum biochemistry, urinalysis, blood pressure, and body condition score before initiating therapy | | Renal risk | Chronic kidney disease (IRIS stage 2 or higher) warrants caution or alternative analgesia | | Gastrointestinal risk | History of vomiting, anorexia, or inflammatory bowel disease increases ulceration risk | | Monitoring interval | Recheck biochemistry and blood pressure at 2 to 4 weeks, then every 3 to 6 months | | Adverse event triggers | Azotemia, proteinuria, hypertension, or gastrointestinal signs mandate dose reduction or discontinuation | | Regulatory status | Use only products with feline label approval or published safety data, consult current regulatory guidance | ## Cyclooxygenase Biology and the Rationale for Selective Inhibition The therapeutic and toxic effects of NSAIDs converge on the cyclooxygenase enzymes. Two isoforms, COX-1 and COX-2, were identified in the early 1990s, with COX-1 characterized as constitutively expressed in most tissues and COX-2 as inducible, localized primarily to inflammatory cells and tissues. In an animal model of acute inflammation, a selective COX-2 inhibitor reduced edema and provided analgesia without suppressing gastric prostaglandin production or causing gastric toxicity, whereas nonselective agents produced both therapeutic and adverse effects through concurrent COX-1 inhibition. This foundational work established the rationale for developing COX-2 selective drugs with an improved gastrointestinal safety profile. The distinction is not absolute. COX-2 is constitutively expressed in the kidney, where it contributes to renal hemodynamics under conditions of reduced perfusion, and in the gastrointestinal tract, where it participates in mucosal repair. Consequently, selective COX-2 inhibitors reduce but do not eliminate renal and gastrointestinal risk. The clinical implication is that selectivity informs risk stratification but does not justify complacency in monitoring. ## Feline Drug Handling and Its Therapeutic Consequences Cats display a well-documented deficiency in hepatic glucuronidation, the phase II conjugation pathway that many NSAIDs require for elimination. This metabolic limitation prolongs the half-lives of drugs such as carprofen and meloxicam in cats relative to dogs, and it explains why dosing intervals and total daily doses for cats often differ substantially from canine regimens. The practical consequence is that extrapolating canine doses to cats is unsafe, and label-specific feline dosing must be followed. The feline kidney also presents unique considerations. Cats have a high basal sympathetic tone and a renin-angiotensin-aldosterone system that is sensitive to prostaglandin-mediated vasodilation. When renal perfusion is threatened by dehydration, hypotension, or preexisting kidney disease, renal prostaglandins become essential for maintaining glomerular filtration. NSAID-induced suppression of these prostaglandins can precipitate acute kidney injury, particularly in older cats with subclinical renal impairment. This mechanism underlies the recommendation to assess renal function before initiating therapy and to recheck it at defined intervals. ## Evidence Base for NSAID Use in Feline Chronic Pain The evidence supporting NSAID use in feline degenerative joint disease has grown over the past two decades, but it remains less robust than the canine literature. Several randomized, blinded, placebo-controlled trials have demonstrated improvements in activity monitoring and owner-assessed mobility with daily meloxicam and with robenacoxib. These studies, however, are limited by relatively short durations, modest sample sizes, and variable outcome measures. The long-term safety data, particularly for therapy extending beyond six months, derive largely from open-label extension studies and retrospective analyzes instead of prospective controlled trials. A separate body of evidence, drawn from human medicine, informs the understanding of COX-2 in chronic inflammatory conditions. Reviews of COX-2 expression in colorectal cancer and inflammatory bowel disease have shown that elevated COX-2 is associated with worse survival, and that NSAIDs reduce prostaglandin production primarily through COX-2 inhibition. While these findings do not translate directly to feline osteoarthritis, they reinforce the biological plausibility of targeting COX-2 for chronic inflammatory pain. Similarly, epidemiological and animal model data on NSAIDs in Alzheimer disease have demonstrated that traditional NSAIDs, but not selective COX-2 inhibitors, reduced pathology in transgenic models, a finding that highlights the isoform-specific effects that vary by tissue and disease state. The relevance to feline practice is cautionary: COX-2 selectivity is not uniformly beneficial across all inflammatory contexts. ## Selecting an NSAID for the Individual Cat Selection begins with a diagnosis. Chronic pain in cats is often attributed to degenerative joint disease on the basis of radiography, but the correlation between radiographic changes and clinical signs is imperfect. A trial of therapy, with objective assessment of mobility, grooming, and temperament, may be more informative than imaging alone. Before prescribing, the clinician should document baseline renal and hepatic biochemistry, urinalysis with specific gravity and protein-to-creatinine ratio, and systolic blood pressure. Cats with IRIS stage 2 chronic kidney disease or higher, uncontrolled hypertension, or a history of gastrointestinal ulceration are poor candidates for NSAID monotherapy. Among the NSAIDs with feline label approval in various jurisdictions, meloxicam and robenacoxib have the most published safety data for chronic use. Both are preferentially COX-2 selective, though robenacoxib has higher selectivity in ex vivo feline assays. The choice between them often rests on formulation, dosing convenience, and individual patient response instead of on demonstrated superiority in safety outcomes. Current formulary and label references must be consulted for approved doses and durations, as these vary by country and product. ## Monitoring Protocol and Adverse Event Recognition Monitoring is not optional. The clinician should schedule a recheck at 2 to 4 weeks after initiation, repeating serum biochemistry, urinalysis, and blood pressure measurement. Thereafter, rechecks every 3 to 6 months are appropriate for cats on continuous therapy. Owners should be instructed to report vomiting, diarrhea, inappetence, lethargy, or increased thirst, as these signs may precede laboratory abnormalities. The most common adverse events are gastrointestinal and renal. Gastrointestinal signs may occur even with selective COX-2 inhibitors, given the role of COX-2 in mucosal defense. Renal adverse events are typically detected as rising creatinine or declining urine specific gravity. Hypertension, defined according to the American College of Veterinary Internal Medicine consensus guidelines, warrants intervention and reconsideration of NSAID therapy. Hepatic enzyme elevations are less common but should trigger evaluation of concurrent medications and consideration of dose reduction. When an adverse event occurs, the NSAID should be discontinued, supportive care initiated, and the underlying cause investigated. Rechallenge at a lower dose may be considered in selected cases, but only after resolution of the adverse event and with owner consent to close monitoring. The decision to continue or stop therapy should be documented in the medical record, along with the rationale. ## Pretreatment Assessment and Risk Stratification The decision to prescribe an NSAID for chronic feline pain begins with a structured assessment that identifies contraindications, relative risks, and baseline values for later comparison. A minimum database includes serum biochemistry with renal parameters, urinalysis with urine specific gravity, total thyroxine, and systolic blood pressure measurement. This panel detects preclinical chronic kidney disease (CKD), hyperthyroidism, and systemic hypertension, each of which alters drug selection or monitoring intensity. History taking should target prior NSAID or corticosteroid exposure, episodes of vomiting or inappetence, polyuria or polydipsia, and current medications. Concurrent glucocorticoid use is an absolute contraindication to NSAID therapy because the combination markedly increases gastrointestinal injury and renal risk. The [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary) provides label-based contraindications and adverse event reporting pathways that inform this assessment. Physical examination adds body condition score, muscle condition score, hydration status, and abdominal palpation for renal size or pain. Cats with suspected dehydration, hypovolemia, or hypotension should not receive an NSAID until volume status is corrected, because renal prostaglandin dependence increases under these conditions. The constitutive and inducible cyclooxygenase model explains this vulnerability: COX-1 maintains renal perfusion and gastric mucosal integrity, while COX-2 mediates inflammation and pain, as demonstrated in early pharmacological studies of selective inhibition [Seibert et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7991575/). ## NSAID Selection Based on Comorbid Conditions Drug selection follows risk stratification instead of a one-size-fits-all approach. The table below integrates common feline comorbidities with selection logic and monitoring adjustments. | Comorbidity | Preferred approach | Avoid or use with caution | Monitoring adjustment | |---|---|---|---| | Chronic kidney disease IRIS stage 1 | COX-2 preferential NSAID at lowest effective dose | NSAIDs in IRIS stage 3 or 4 | Recheck creatinine and SDMA at 2 weeks, then every 3 months | | Systemic hypertension | NSAID only if blood pressure controlled | NSAIDs with uncontrolled hypertension | Repeat blood pressure at 2 weeks | | Hepatic disease | Short-acting NSAID, reduced dose | NSAIDs with severe hepatic insufficiency | Monitor appetite, bilirubin, ALT at 4 weeks | | Gastrointestinal history | COX-2 preferential agent, consider gastroprotectant | NSAIDs with recent perforation or bleeding | Monitor for vomiting, melena, inappetence | | Diabetes mellitus | No specific contraindication | Avoid concurrent corticosteroids | Monitor glucose and appetite | | Hyperthyroidism | Treat thyroid disease first | NSAIDs before euthyroid status | Recheck T4 and renal values after stabilization | | Cardiac disease | NSAID acceptable if stable | NSAIDs with decompensated heart failure | Monitor body weight, respiratory rate | The evidence base for selective COX-2 inhibition in pain and inflammation derives largely from experimental models showing that selective inhibitors reduce edema and pain without gastric toxicity [Seibert et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7991575/). Translating this to feline clinical practice requires recognition that COX-2 also serves constitutive functions in the kidney and gastrointestinal tract, so selectivity reduces but does not eliminate risk. For cats with osteoarthritis and no comorbidity, a COX-2 preferential NSAID approved for cats is the standard first choice. For cats with IRIS stage 2 CKD, the same agent may be used at the lowest effective dose with intensified monitoring, provided the cat is well hydrated and eating. For cats with a history of gastrointestinal ulceration, an NSAID is relatively contraindicated, and alternative analgesics should be considered. ## Monitoring Schedule and Parameter Interpretation Monitoring serves two purposes: detecting adverse effects before they become irreversible and confirming that the drug provides meaningful pain relief. A structured schedule reduces the likelihood that subtle toxicity goes unnoticed until crisis. Baseline values are established at the pretreatment visit. The first recheck occurs at 7 to 14 days after starting therapy. This visit repeats serum creatinine, SDMA, urinalysis, and blood pressure, and includes a structured owner interview about appetite, vomiting, fecal character, and activity. A second recheck at 4 to 6 weeks confirms stability. Thereafter, monitoring every 3 to 6 months matches the chronic nature of the therapy. Each parameter detects a specific failure mode. Serum creatinine and SDMA detect declining glomerular filtration rate, which may indicate renal ischemia from prostaglandin inhibition. Urine specific gravity below 1.035 in a hydrated cat suggests impaired concentrating ability. Blood pressure elevation may reflect renal dysfunction or unmask latent hypertension. Appetite loss and vomiting are early indicators of gastrointestinal injury, often preceding melena or hematemesis. Weight loss may indicate inadequate pain control or chronic nausea. Owner-reported outcomes are equally important. A simple pain scoring instrument, such as a client-specific outcome measure or a validated feline mobility questionnaire, should be completed at each visit. Improvement in mobility, grooming, and social interaction confirms therapeutic efficacy. Lack of improvement after 2 to 4 weeks at an adequate dose warrants reassessment of the diagnosis, dose, or drug choice. ## Troubleshooting Adverse Effects When an adverse effect occurs, the response depends on its nature and severity. Gastrointestinal signs such as vomiting, diarrhea, or reduced appetite require immediate drug discontinuation. Supportive care includes gastroprotectants, antiemetics, and fluid therapy if dehydration is present. Most cats recover within days of drug withdrawal, but severe ulceration may require more intensive management. Renal adverse effects manifest as azotemia, reduced urine output, or declining urine specific gravity. The NSAID should be stopped, and fluid therapy initiated to restore perfusion. Renal values typically improve within days, although preexisting CKD may be unmasked or accelerated. [The MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on renal disease management and drug adjustments that supports this decision process. Hepatic adverse effects are less common but occur, particularly in cats with preexisting liver disease. Elevated ALT, bilirubin, or reduced appetite warrants drug discontinuation and liver support. Recovery is usually complete if the drug is stopped early. Hypertension discovered during monitoring requires drug discontinuation or dose reduction, followed by antihypertensive therapy if blood pressure remains elevated. The NSAID may be restarted at a lower dose once blood pressure is controlled, but only if the benefit clearly outweighs the risk. ## Documentation and Client Communication Medical records should document the indication for NSAID therapy, baseline laboratory values, drug and dose prescribed, the monitoring schedule, and owner instructions for recognizing adverse effects. Each recheck visit should record the parameters measured, the pain score, and the decision to continue, adjust, or discontinue therapy. Client communication should emphasize that adverse effects can occur at any time, also at scheduled rechecks. Owners should be instructed to stop the medication and contact the clinic if vomiting, inappetence, lethargy, or changes in urination occur. Written instructions reinforce verbal communication and reduce the risk of delayed reporting. The [AVMA practice resources](https://www.avma.org/resources-tools) offer additional guidance on professional communication and practice standards that support consistent documentation and client education. Clear records also facilitate continuity when another clinician assumes the case. ## Species-Specific and Regional Considerations Feline NSAID use differs from canine use in several respects. Cats have limited glucuronidation capacity, which prolongs the half-life of some NSAIDs and increases the risk of accumulation. They also have a narrower therapeutic index for many agents, so dose accuracy and owner compliance with the prescribed regimen are critical. Regional differences in drug availability and regulatory status affect prescribing choices. Some NSAIDs approved for cats in one country are not available in another. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address international harmonization of veterinary drug regulation, but practitioners must consult their local regulatory authority and current formularies for approved products and withdrawal requirements. Extralabel use of NSAIDs approved for other species is possible in some jurisdictions under veterinary oversight, but this requires a valid veterinarian-client-patient relationship and informed client consent. Production status also matters. NSAIDs are not used in food-producing cats, so this consideration applies only to breeding or performance animals. In breeding queens, NSAID use during pregnancy or lactation is generally avoided due to limited safety data, and alternative analgesia should be considered. ## Recognized Complications and Early Detection Chronic NSAID therapy in cats can produce adverse effects that are clinically silent until advanced. Gastrointestinal injury, renal function decline, and hepatopathy constitute the principal recognized complications. Each has a characteriztic temporal pattern and laboratory signature. Gastrointestinal adverse effects range from subtle appetite loss to perforating ulceration. Vomiting, melena, and cranial abdominal pain are late signs. Early detection depends on serial assessment of body weight, appetite reports from the owner, and fecal inspection for occult blood. Serum albumin decline without another explanation can indicate protein-losing enteropathy from chronic mucosal erosion. The COX-2 selectivity of a drug does not eliminate gastrointestinal risk, since constitutive COX-1 in feline gastric mucosa still requires preservation and even selective inhibitors carry some risk in susceptible individuals [Seibert et al., pharmacological and biochemical demonstration of COX-2 in inflammation and pain](https://pubmed.ncbi.nlm.nih.gov/7991575/). Renal adverse effects arise from prostaglandin-dependent afferent arteriolar vasodilation in the hypoperfused kidney. Dehydration, hypotension, concurrent diuretic use, and pre-existing chronic kidney disease (CKD) amplify this risk. Early detection requires serum creatinine and symmetric dimethylarginine (SDMA) measurement before therapy, at the first recheck, and then at intervals determined by the cat's baseline renal status. A creatinine increase of more than 30 percent from baseline, or a rise that crosses the reference interval, warrants dose reduction or drug withdrawal. Urine specific gravity below 1.035 in a hydrated cat with azotaemia supports renal causation. Hepatopathy is less common but well recognized. Anorexia, lethargy, and jaundice may appear weeks to months after therapy begins. Baseline alanine aminotransferase (ALT) and alkaline phosphatase (ALP) measurements are mandatory. A threefold or greater ALT increase above the reference interval, or any increase accompanied by clinical signs, justifies discontinuation and rechecking in 7 to 14 days. ## Common Clinical Errors and Corrective Actions The most frequent error is prescribing an NSAID without a complete pretreatment database. A cat with normal physical examination findings can still have subclinical CKD or hepatopathy. Baseline serum biochemistry, urinalysis, and total thyroxine measurement in older cats are not optional when chronic therapy is planned. A second error is failing to adjust the monitoring interval to the individual cat. A fixed 6 month recheck schedule does not serve a cat with stage 2 CKD or one that has experienced dehydration from any cause. Monitoring frequency should be stratified by baseline risk, with higher risk cats rechecked at 2 to 4 weeks after initiation and then every 3 months. A third error is combining an NSAID with a corticosteroid, whether systemically or topically. The additive gastrointestinal and renal injury is well documented and this combination is contraindicated. Less obvious but equally important is the concurrent use of another NSAID, including those in compounded products or human formulations obtained by owners. A fourth error is continuing therapy despite an intercurrent illness that causes anorexia or vomiting. The owner should be instructed to withhold the next dose and contact the practice if the cat stops eating for more than 24 hours. This instruction must be written, not verbal, and repeated at every recheck. ## Limitations of the Evidence and Divergent Expert Opinion The feline NSAID evidence base is narrower than the canine one. Few randomised controlled trials evaluate chronic dosing beyond 28 days, and most published data address osteoarthritis instead of other chronic pain conditions. Extrapolation from human and rodent data on COX-2 biology is reasonable for mechanism but not for species-specific safety thresholds [Wang and Dubois, the role of COX-2 in intestinal inflammation and colorectal cancer](https://pubmed.ncbi.nlm.nih.gov/19946329/). Expert opinion diverges on three questions. First, whether any NSAID can be used safely in a cat with International Renal Interest Society stage 3 CKD. Some specialists will use a low dose with intensive monitoring, while others regard this as an absolute contraindication. Second, whether routine urinalysis at every recheck is necessary or whether serum creatinine and SDMA suffice. Third, whether a washout period is required when switching between NSAIDs, and if so, its duration. Published guidance does not resolve these questions, and the practitioner should document the reasoning behind each decision. ## Referral, Consultation, and Regulatory Reporting Referral to a specialist is warranted when a cat requires an NSAID but has concurrent disease that makes selection and monitoring beyond the comfort of the general practitioner, when adverse effects are severe or recurrent, or when pain control remains inadequate despite optimization. Specialist consultation is also appropriate for cats requiring long-term therapy after a previous NSAID-related adverse event. Laboratory involvement extends beyond routine biochemistry. A veterinary clinical pathologist can assist with interpretation of serial trends, particularly when baseline values are borderline. Histopathology of a liver or kidney biopsy may be needed when drug-induced injury is suspected but the diagnosis is uncertain. Regulatory reporting of suspected adverse drug reactions is a professional obligation. The United States Food and Drug Administration Center for Veterinary Medicine maintains the adverse event reporting system for approved animal drugs, and reports can be submitted electronically [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary). Reporting does not imply causation and serves the broader professional community. Similar reporting systems exist in other jurisdictions, and the practitioner should be familiar with the mechanism in their own country. | Observation | Likely Cause | Discriminating Check | | --- | --- | --- | | Anorexia within 3 to 7 days of starting therapy | Gastrointestinal irritation or nausea | Fecal occult blood, abdominal ultrasound, trial of dose reduction | | Azotaemia at first recheck | Preexisting CKD unmasked by NSAID | Baseline creatinine and SDMA comparison, urine specific gravity | | Azotaemia after a dehydrating illness | Prerenal or renal prostaglandin dependence | Hydration status, urine specific gravity, repeat creatinine after fluid therapy | | ALT increase above threefold baseline | Drug-induced hepatopathy | Bilirubin, bile acids, hepatic ultrasound, consider biopsy | | Vomiting with melena | Gastroduodenal ulceration | Fecal occult blood, packed cell volume, endoscopic evaluation | | Appetite normal but weight loss | Chronic low-grade gastrointestinal loss or inadequate analgesia | Serial body weight, fecal occult blood, owner pain scoring | ## Frequently Asked Questions ### How Should I Manage a Cat With Suspected NSAID Toxicity When Immediate Veterinary Care Is Unavailable? Stabilization precedes decontamination. If ingestion occurred within two hours and the cat is alert, induction of emesis may be considered, but only when the airway is protected and no contraindications exist. Activated charcoal can be administered if the cat is not vomiting. Do not attempt home decontamination in a depressed or seizuring cat. Fluid therapy, gastrointestinal protectants, and monitoring of renal and hepatic parameters require hospitalization. Owners should contact a veterinary emergency service or animal poison control center for case-specific guidance. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains adverse event reporting pathways that can supplement clinical decision-making in suspected toxicity cases. ### What Monitoring Is Feasible When the Owner Has Limited Financial Resources? Prioritize monitoring that detects the most common and most dangerous adverse effects first. A baseline biochemistry panel measuring renal and hepatic parameters is the minimum pretreatment assessment. If follow-up laboratory testing is unaffordable, instruct owners to monitor appetite, water intake, vomiting episodes, and stool character daily. Reduced appetite or increased thirst warrants immediate drug cessation and reassessment. Urine specific gravity can be measured in-house at low cost and provides useful renal information. Discuss the option of a short therapeutic trial with scheduled reassessment instead of indefinite dispensing. Document the monitoring limitations in the medical record and obtain informed consent acknowledging the reduced safety net. ### How Do I Explain the Risks and Benefits of Long-Term NSAID Therapy to a Client Who Is Reluctant to Use Daily Medication? Frame the discussion around quality of life and risk stratification. Explain that chronic pain itself carries physiologic costs, including reduced mobility, poor sleep, and behavioral changes. NSAIDs target cyclooxygenase enzymes that mediate both inflammation and pain, and selective COX-2 inhibition was developed specifically to preserve gastrointestinal protective prostaglandins while reducing inflammatory mediators, as demonstrated in early pharmacological studies of selective inhibitors [Seibert et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7991575/). Contrast this with the risks of untreated pain. Describe the monitoring schedule as a partnership: you will reassess laboratory values and clinical response at defined intervals, and the drug will be discontinued if concerns arise. Provide written instructions for adverse effect recognition and emergency contact information. ### What Records Should I Maintain for a Cat Receiving Chronic NSAID Therapy? Maintain a structured monitoring log that includes the date of each assessment, body weight, body condition score, pain score using a validated instrument, and results of any laboratory testing. Record the drug, formulation, dose, and dosing interval prescribed. Document client-reported observations including appetite, activity, litter box habits, and any adverse events. Note the rationale for any dose adjustments or drug changes. Include the informed consent discussion and the monitoring plan agreed upon with the owner. This record supports continuity of care if another clinician assumes management and provides documentation if regulatory questions arise. The [AVMA practice resources](https://www.avma.org/resources-tools) offer guidance on medical record standards that apply to chronic therapy cases. ### Can I Use the Same NSAID Monitoring Protocol for a Dog That I Use for a Cat? No. Feline drug handling differs substantially from canine handling, particularly regarding glucuronidation capacity, protein binding, and elimination half-life. Protocols validated for one species should not be extrapolated to the other without adjustment. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific pharmacology and dosing information that should be consulted before prescribing any NSAID. Monitoring intervals, acceptable laboratory values, and adverse effect profiles differ between species. A protocol designed for canine osteoarthritis patients may miss early renal decompensation in a cat or apply an inappropriately long dosing interval. Always verify that the monitoring schedule and dose are appropriate for the species being treated. ### When Should I Refer a Feline Chronic Pain Case to a Specialist? Refer when the cat has complex comorbidities that complicate NSAID selection, when pain remains poorly controlled despite appropriate dose titration and adjunctive therapy, or when adverse effects occur and an alternative analgesic strategy is needed. Referral is also appropriate when you lack access to the diagnostic tools needed for adequate monitoring, such as routine biochemistry or blood pressure measurement. Cases involving suspected renal disease, cardiac disease, or concurrent corticosteroid use benefit from specialist input before NSAID initiation. If the client requests a second opinion or you feel uncertain about the risk-benefit balance, referral serves the patient's interests. Document the reason for referral and communicate the monitoring history to the receiving clinician. ## Related Clinical & Scientific Guides * [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references) * [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary) * [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive) ## References and Further Reading - [The role of COX-2 in intestinal inflammation and colorectal cancer.](https://pubmed.ncbi.nlm.nih.gov/19946329/). 2010. - [EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).](https://pubmed.ncbi.nlm.nih.gov/16707532/). 2006. - [NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.](https://pubmed.ncbi.nlm.nih.gov/16697488/). 2007. - [Low-level laser therapy in acute pain: a systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials.](https://pubmed.ncbi.nlm.nih.gov/16706694/). 2006. - [Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.](https://pubmed.ncbi.nlm.nih.gov/7991575/). 1994. - [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM. - [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. - [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association. ## Related Articles - [NSAID Toxicity in Dogs: Recognition, Management, and Prevention](/knowledge/veterinary-medicine/clinical-pharmacology/nsaid-toxicity-dogs-recognition-management-prevention) - [Corticosteroid Therapy in Feline Diseases: Special Considerations](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-feline-diseases-special-considerations) - [Drug Interactions with NSAIDs in Veterinary Patients: Mechanisms and Clinical Management](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-nsaids-veterinary) - [Corticosteroid Therapy in Feline Inflammatory Bowel Disease: Dosing and Monitoring](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-feline-ibd) - [Therapeutic Decision Framework for Canine Osteoarthritis: NSAIDs, Adjuvants, and Monitoring](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-decision-framework-canine-osteoarthritis) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.